Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that Tang Xiaochun, who served as the head of vaccine business and assistant vice-president at MSD China, has left the company. Tang initially joined MSD China in 2018 as the executive director of the company’s oncology medical affairs department. During his tenure, he played a pivotal role in the successful launch of multiple indications for Keytruda, MSD’s leading anti-PD-1 therapy.
In a leadership shuffle announced by MSD China on January 5, 2021, Tang succeeded Peng Laili as the head of the vaccine business unit, a position from which he has now departed.
In related news, HutchMed (HKG: 0013, NASDAQ: HCM) has revealed that Yuan Zezhi, known as George, who was previously with MSD, joined the company on June 1, 2024, as Executive Vice-President and Head of Commercialization. Reporting directly to HutchMed’s CEO Su Weiguo, Yuan brings extensive experience from his time as the head of MSD’s China medical and health business oncology division.- Flcube.com
